Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Organisation › Details

BiomX Inc. (NYSE: PHGE)

BiomX is a microbiome drug discovery company developing customized phage therapies that seek and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer. We discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. The Company’s platforms use computational and synthetic biology and cutting-edge research from Profs. Rotem Sorek, Ph.D., Eran Elinav, M.D., Ph.D., and Eran Segal, Ph.D., of The Weizmann Institute of Science; and Professor Timothy K. Lu, M.D., Ph.D., of The Massachusetts Institute of Technology. Investors in the Company include OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation Inc., Takeda Ventures, Inc., Seventure Partners, Mirae Asset, and SBI. *

 

Period Start 2017-05-15 renamed before
  Group BiomX (Group)
  Today BiomX Ltd.
  Predecessor MBcure (IL)
Products Industry microbiomics
  Industry 2 phage therapy
Person Person Solomon, Jonathan (BiomX 201705 CEO before Proclara/NeuroPhage 201403 CEO before Israeli military)
     
  City Delaware registered company
  Tel +972-72-3942377
    Address record changed: 2024-01-05
     
Basic data Employees n. a.
     
    �About Section� taken from web site of organisation on 08.03.
     
   
Record changed: 2023-07-10

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for BiomX (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top